Last reviewed · How we verify
gemcitabine, cisplatin and tislelizumab
gemcitabine, cisplatin and tislelizumab is a Small molecule drug developed by Stichting Hemato-Oncologie voor Volwassenen Nederland. It is currently in Phase 2 development.
At a glance
| Generic name | gemcitabine, cisplatin and tislelizumab |
|---|---|
| Sponsor | Stichting Hemato-Oncologie voor Volwassenen Nederland |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- SSRI Antidepressant Fluoxetine Improving Immunotherapy Efficacy in Advanced Hepatobiliary Malignancy Patients With Depression and Anxiety (PHASE2)
- Tislelizumab, Gemcitabine and Cisplatin for R/R Hodgkin Lymphoma Followed by Tislelizumab Consolidation in Patients in Metabolic Complete Remission (PHASE2)
- Tislelizumab Monotherapy Versus Salvage Chemotherapy for Relapsed/Refractory Classical Hodgkin Lymphoma (PHASE3)
- Short-course Tislelizumab Combined With Chemoradiotherapy for Nasopharyngeal Carcinoma (PHASE3)
- Study of Tislelizumab in Combination With Chemotherapy Compared to Chemotherapy Alone for Participants With Urothelial Carcinoma (PHASE3)
- Propranolol With Tislelizumab Plus GC in Neoadjuvant Bladder UC (PHASE1)
- 40.2Gy Versus 49.2Gy Radiotherapy in Low-Risk Target Volume for Chemosensitive Stage II Nasopharyngeal Carcinoma (PHASE3)
- Neoadjuvant Zanidatamab + Tislelizumab + Chemotherapy for Selective Bladder Preservation in HER2-Positive MIBC (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- gemcitabine, cisplatin and tislelizumab CI brief — competitive landscape report
- gemcitabine, cisplatin and tislelizumab updates RSS · CI watch RSS
- Stichting Hemato-Oncologie voor Volwassenen Nederland portfolio CI
Frequently asked questions about gemcitabine, cisplatin and tislelizumab
What is gemcitabine, cisplatin and tislelizumab?
gemcitabine, cisplatin and tislelizumab is a Small molecule drug developed by Stichting Hemato-Oncologie voor Volwassenen Nederland.
Who makes gemcitabine, cisplatin and tislelizumab?
gemcitabine, cisplatin and tislelizumab is developed by Stichting Hemato-Oncologie voor Volwassenen Nederland (see full Stichting Hemato-Oncologie voor Volwassenen Nederland pipeline at /company/stichting-hemato-oncologie-voor-volwassenen-nederland).
What development phase is gemcitabine, cisplatin and tislelizumab in?
gemcitabine, cisplatin and tislelizumab is in Phase 2.